JCM
RNTX

Jacobi Capital Management’s Rein Therapeutics RNTX Stock Holding History

Jacobi Capital Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25
Closed -$1K – 1372
2021
Q3 		$1K Hold
25
– – ﹤0.01% 1423
2021
Q2 		$1K Hold
25
– – ﹤0.01% 1368
2021
Q1 		$1K Buy
+25
New +$857 ﹤0.01% 1338

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Jacobi Capital Management's RNTX Position: Q4 2021 in Review

Jacobi Capital Management sold out of Rein Therapeutics (RNTX) in Q4 2021, closing a stake of 25 shares — an estimated $1K sold.

Jacobi Capital Management first reported a position in RNTX in Q1 2021 and held it in 3 quarters. The position peaked at $1K in Q3 2021. 43 funds tracked by Wall St. Rank hold RNTX as of Q4 2021.

  • Jacobi Capital Management reported no remaining Rein Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Jacobi Capital Management sold 25 Rein Therapeutics shares in Q4 2021, an estimated $1K.
  • Jacobi Capital Management first reported a position in Rein Therapeutics in Q1 2021 and held it in 3 quarters.
  • Jacobi Capital Management's Rein Therapeutics position peaked at $1K in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2021.

Based on Jacobi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.